Galectin-9在卵巢癌中的表达及其意义

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore expression of Galectin-9 in ovarian cancer tissue and correlation with clinical pathological features. Methods 60 ovarian cancer tissues in our hospital from May 2013 to May 2015 were selected as the research group，at the same time，50 cases of benign tumor resection were selected as control group.Expression of Galectin-9 in cancer and benign tumor ovarian tissues were detected by immunohistochemistry method.Relationship between expression of Galectin-9 and clinical pathological features in ovarian cancer tissues was analyzed. Results Galectin-9 was located in the nucleus or cytoplasm.47 cases（94%）was expressed by Galectin-9 in 50 cases of benign ovarian tumor tissues，which was higher than 26 cases（43.33%）in 60 ovarian cancer tissues，with significant difference （P＜0.01）.Galectin-9 positive expression rate in ovarian cancer tissues with different clinical stages，different pathological grades，and presence of lymph node metastasis was different，with significant difference（P＜0.01）. Conclusion Galectin-9 expression is low in ovarian cancer tissues，and it is related to pathological grades，lymphatic metastasis and clinical stages，which may be closely related to the occurrence，development and prognosis of ovarian cancer.

Key words： Ovarian cancer Galectin-9 Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PAN Li-ying
	HUANG Fu-hai
	ZHONG Xue-hua

Cite this article:

PAN Li-ying,HUANG Fu-hai,ZHONG Xue-hua. ExPression and significance of Galectin-9 in ovarian cancer[J]. 中国当代医药, 2016, 23(11): 36-38.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I11/36

［1］	Jaramillo MC，Zhang DD.The emerging role of the Nrf2-Keap1 signaling pathway in cancer［J］.Genes Dev，2013，27 （20）：2179-2191.
［2］	Qiu Y，Li P，Ji C.Cell Death conversion under hypoxic condition in tumor development and therapy［J］.Int J Mol Sci，2015，16（10）：25536-25551.
［3］	Maremanda NG，Roy K，Kanwar RK，et al.Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells［J］.Biomicrofluidics，2015，9（5）：054110.
［4］	Fujihara S，Mori H，Kobara H，et al.Galectin-9 in cancer therapy［J］.Recent Pat Endocr Metab Immune Drug Discov，2013，7（2）：130-137.
［5］	向江东，席晓薇.半乳凝素-9与肿瘤［J］.现代肿瘤医学，2010，18（5）：1014-1016.
［6］	顾长江，吴寒盛，陈毅，等.半乳凝素9在肝细胞肝癌患者中的表达及其与预后的关系［J］.中华医学杂志，2013，93（26）：2025-2028.
［7］	安宁，王建军.半乳凝素-9蛋白在肺腺癌、鳞癌中的表达及意义［J］.中华临床医师杂志·电子版，2011，5（24）：7374-7376.
［8］	姬社青，陈小兵，张斌.半乳糖凝集素在胃癌患者血清及肿瘤组织中的表达［J］.中华实验外科杂志，2015，32（7）：1680-1682.
［9］	International Union Against Cancer.TMN classification of malignant tumours［M］.6thed.NewYork（NY）：Wiley，2002：102.
［10］	许良中，杨文涛.免疫组织化学反应结果的判断标准［J］.中国癌症杂志，1996，6（4）：229-231.
［11］	赵安成.肿瘤五项标志联合检测对卵巢癌诊断的应用价值探讨［J］.中华肿瘤防治杂志，2012，19（15）：1184-1186.
［12］	周冬梅，生秀杰，娄思园，等.BRMSI基因对卵巢癌细胞侵袭转移作用及其机制的探讨［J］.中华肿瘤防治杂志，2011，18（15）：1161-1165.
［13］	张丰，郑民华.半乳凝素-9的研究进展［J］.上海交通大学学报·医学版，2007，27（12）：1501-1505.
［14］	McSharryBP，ForbesSK，CaoJZ，etal.Humancytomegalovirus upregulates expression of the lectin galectin 9 via induction of beta interferon［J］.J Virol，2014，88（18）：10990-10994.
［15］	Chan SW，Kallarakkal TG，Abraham MT.Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers［J］. Asian Pac J Cancer Prev，2014，15（5）：2145-2152.
［16］	Thijssen VL，Heusschen R，Caers J，et al.Galectin expression in cancer diagnosis and prognosis：a systematic review［J］.Biochim Biophys Acta，2015，1855（2）：235-247.
［17］	张丰，计骏，蔡劬，等.结直肠癌中Galectin-9的表达及其意义［J］.肿瘤，2008，28（5）：419-422.
［18］	姚众，陈为亮，徐洋洋，等.半乳凝素-9抑制胶质瘤细胞增殖及迁移［J］.山东大学学报·医学版，2015，53（4）：1-5.
［19］	Lahm H，André S，Hoeflich A，et al.Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures［J］.J Cancer Res Clin Oncol，2001，127 （6）：375-386.
［20］	Niwa H，Satoh T，Matsushima Y，etal.Stableformofgalectin-9，a Tim-3 ligand，inhibits contact hypersensitivity and psoriatic reactions：a potent therapeutic tool for Th1-and/ or Th17-mediated skin inflammation［J］.Clin Immunol，2009，132（2）：184-194.